CTAS
62
7
OKE
59
3
NTRS
35
5
ADM
34
-2
SWK
55
3
CF
35
2
GD
66
2
PNW
57
-9
ALLE
39
-9
SE
57
5
AAPL
71
10
SEE
57
2
BLK
61
3
MHK
55
2
PNC
52
3
EMC
89
15
DLTR
46
2
ZBH
54
3
MTCH
55
5
ROP
65
2
CTAS
62
7
OKE
59
3
NTRS
35
5
ADM
34
-2
SWK
55
3
CF
35
2
GD
66
2
PNW
57
-9
ALLE
39
-9
SE
57
5
AAPL
71
10
SEE
57
2
BLK
61
3
MHK
55
2
PNC
52
3
EMC
89
15
DLTR
46
2
ZBH
54
3
MTCH
55
5
ROP
65
2
Financhill
Back

Recursion Pharmaceuticals 10K Form

Buy
62

RXRX
Recursion Pharmaceuticals

Last Price:
9.05
Seasonality Move:
67.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RXRX News And Ratings

See the #1 stock for the next 7 days that we like better than RXRX

RXRX Financial Statistics

Sales & Book Value

Annual Sales: $43.88M
Cash Flow: $-76.49M
Price / Cash Flow: 0
Annual Sales: $1.98
Price / Book: 4.48

Profitability

EPS (TTM): -1.57000
Net Income (TTM): $-328.07M
Gross Margin: $1.29M
Return on Equity: -71.75%
Return on Assets: -50.01%

Recursion Pharmaceuticals Earnings Forecast

Key Recursion Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 4 years for RXRX is 2.94%.
  • The Selling, General & Administrative Expenses for RXRX have been equal to 252.58% of Gross Profit Margin.
  • The Research & Development expenses have been 549.79% of Revenue.
  • The Interest Expense is -0.03% of Operating Income.
  • The Net Earning history of RXRX is -747.71% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Recursion Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: RXRX
Website: recursion.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.7
Quick Ratio: 4.24

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RXRX Technical Analysis vs Fundamental Analysis

Buy
62
Recursion Pharmaceuticals (RXRX) is a Buy

Is Recursion Pharmaceuticals a Buy or a Sell?